# Olverembatinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/olverembatinib

> The next catalyst for olverembatinib, sponsored by ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG), is its topline data readout, Mar to Jun 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | olverembatinib |
| Codes | HQP1351 |
| Sponsor | ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) https://sec-api.dev/companies/aapg/catalysts |
| Indications | [GIST](https://sec-api.dev/indications/gist), Ph+ ALL, Chronic Myeloid Leukemia |
| Modality | small_molecule |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### Feb 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-27, last confirmed 2025-04-17.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-032670): "After receiving clearance from the FDA in February 2024 , we commenced enrollment in a registrational Phase III clinical trial of olverembatinib for previously treated CML - CP patients, both with and without T 315 I mutation (POLARIS - 2 ) ." https://www.sec.gov/Archives/edgar/data/2023311/000121390025032670/ea0238587ex99-1_ascentage.htm
- Press release filed with the SEC (EX-99) (accession 0001013762-25-003350): "After receiving clearance from the FDA in February 2024, we commenced enrollment in a registrational Phase III clinical trial of olverembatinib for previously treated CML-CP patients, both with and without T315I mutation (POLARIS-2)." https://www.sec.gov/Archives/edgar/data/2023311/000101376225003350/ea023588201ex99-1_ascent.htm

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: GIST.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06640361 (A Study of Olverembatinib in SDH-deficient GIST.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." https://clinicaltrials.gov/study/NCT06640361

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: GIST.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06640361 (A Study of Olverembatinib in SDH-deficient GIST.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." https://clinicaltrials.gov/study/NCT06640361

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Myeloid Leukemia; CML; CML, Chronic Phase.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06423911 (Study of Olverembatinib (HQP1351) in Patients With CML-CP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." https://clinicaltrials.gov/study/NCT06423911

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Myeloid Leukemia; CML; CML, Chronic Phase.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06423911 (Study of Olverembatinib (HQP1351) in Patients With CML-CP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." https://clinicaltrials.gov/study/NCT06423911

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06051409 (A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." https://clinicaltrials.gov/study/NCT06051409

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06051409 (A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." https://clinicaltrials.gov/study/NCT06051409

## Same indication

- [Tasigna (nilotinib hydrochloride)](https://sec-api.dev/pdufa/nilotinib) (NVS)

Calendar months: [March 2027](https://sec-api.dev/fda-calendar/2027-03), [June 2027](https://sec-api.dev/fda-calendar/2027-06), [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/olverembatinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Olverembatinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/olverembatinib

```bibtex
@misc{secapidev_pdufa_olverembatinib_20261116,
  title        = {Olverembatinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/olverembatinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_olverembatinib_20261116","title":"Olverembatinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/olverembatinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
